Clinical Trial Update: Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 study reports on the safety and tolerability of Carboxyamidotriazole Orotate (CTO) in solid tumors and in combination with temozolomide (Temodar) with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• Carboxyamidotriazole Orotate (carboxyamidotriazole orotate)
• Temodar (Temozolomide)

Snippet

Sponsor: Tactical Therapeutics, Inc. | Conditions: Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas | Phase 1 | Status: UNKNOWN